Trials / Conditions / Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

11 registered clinical trials studyying Metastatic Malignant Melanoma.

Status	Trial	Sponsor	Phase
Completed	Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis NCT07256184	Ankara Etlik City Hospital	—
Active Not Recruiting	Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma NCT07428252	Institute of Oncology Ljubljana	N/A
Unknown	Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma NCT02617849	Wilson Miller	Phase 2
Terminated	Bevacizumab vs Dacarbazine in Metastatic Melanoma NCT01705392	Haukeland University Hospital	Phase 2
Completed	A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma NCT01654692	Italian Network for Tumor Biotherapy	Phase 2
Terminated	Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma NCT00961844	Steinar Aamdal	Phase 1 / Phase 2
Completed	Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma NCT00625768	Antisoma Research	Phase 1
Completed	A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma NCT00533702	Eli Lilly and Company	Phase 2
Completed	Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study NCT00462423	Lynn E. Spitler, MD	Phase 2
Terminated	Temodar and Sutent as Therapy for Melanoma NCT00304200	Northern California Melanoma Center	Phase 1 / Phase 2
Completed	Inducing Systemic Immunity and Regressions in Metastatic Melanoma NCT02350972	NYU Langone Health	Phase 1